Takeda Chemical Industries, Inc.

Takeda Pharmaceutical Company Limited

Tatsumi Matsumoto

Yasuko Ashida

Akio Miyake

Mitsuru Shiraishi

Osamu Uchikawa

Yasuhiko Kawano

Naoki Tarui

Nobuhiro Fujii

Yumiko Uno

Masakazu Ichinose

Hiromasa Ogawa

Masafumi Tomaki

Makoto Furusawa

It is intended to provide a compound inhibiting the activity of a protein having an amino acid sequence which is the same or substantially the same as one of the amino acid sequences represented by SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62 and so on, or its salt; a compound inhibiting the expression of a gene of the above protein; an antisense nucleotide containing a base sequence which is complementary or substantially complementary to the base sequence of a DNA encoding the above protein or its partial peptide or a part of the base sequence; an antibody against the above protein or its partial peptide; and so on. The above compound, antisense nucleotide, antibody and so on are usable as a prophylactic/therapeutic agent for respiratory diseases, etc.

Preventive/remedy for respiratory diseases

A compound having a partial structure represented by Formula:or a salt thereof has an excellent phosphodiesterase (PDE) IV-inhibiting effect, and is useful as a prophylactic or therapeutic agent against inflammatory diseases, for example, bronchial asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, autoimmune disease, diabetes and the like.

Furoisoquinoline derivatives, process for producing the same and use thereof

A method for treating allergic rhinitis by administrating to a subject in need thereof an effective amount of a compound of the formula: ##STR1## wherein R.sup.2 and R.sup.3 independently represent a hydrogen atom or a C.sub.1-4 alkyl group, and R.sup.4a and R.sup.5a independently represent a hydrogen atom or a C.sub.1-4 alkyl group, or a pharmaceutically acceptable salt thereof.

Method for treating allergic rhinitis

A method for inhibiting eosinophil infiltration by administrating to a subject in need thereof an effective amount of a compound of the formula: ##STR1## wherein R.sup.2 and R.sup.3 independently represent a hydrogen atom or a C.sub.1-4 group, and R.sup.4a and R.sup.5a independently represent a hydrogen atom or a C.sub.1-4 alkyl group, or a pharmaceutically acceptable salt thereof.

Eosinophil chemotaxis inhibitor

There is disclosed a pharmaceutical composition for treating or preventing allergic rhinitis which comprises a quinone or hydroquinone derivative having thromboxane A.sub.2 receptor antagonism. This compound is hardly inactivated by in vivo metabolism and can maintain its effective blood level for a long term and exhibit excellent pharmacological activity in a low dose.

Pharmaceutical composition for treating or preventing allergic rhinitis

Growing community of inventors

Osaka, Japan

Tatsumi Matsumoto